Invasive Aspergillosis Therapeutics Market

Report Overview

The global invasive aspergillosis therapeutics market was valued at ~US$ 1,012.5 million in 2021 and is expected to witness a CAGR of ~3.90 % during the forecast period from 2022 to 2030. 

Market Fundamentals 

Aspergillosis is a disease caused by the fungus Aspergillus. Invasive aspergillosis can occur to individuals with a weakened immune system. It is a major cause of morbidity and mortality in immunocompromised patients such as those undergoing chemotherapy or organ transplantation. The availability of novel treatments and diagnostic tests is driving the growth of this market. Growing awareness about the disease among healthcare professionals and patients, increasing healthcare expenditure, and government initiatives for early diagnosis and treatment are some other factors contributing to the growth of this market. Aspergillus can cause a variety of disease, including allergic reactions, invasive lung infections, and infections of other organs, depending on the host immune system condition. Lungs and paranasal sinuses are the main infection sites. Early diagnosis and treatment of invasive aspergillosis is crucial as the infection can rapidly become life threatening. Direct invasion from the paranasal sinuses or hematogenous dissemination are the two causes of cerebral involvement.

[8482924]

Market Dynamics

As immunosuppressive therapies are used more frequently, more patients are at risk for developing this condition. Mostly, people who experienced organ transplantation are undergoing immunosuppressive therapies. High recommendation of voriconazole by healthcare professionals is increasing the market value. Furthermore, rising COPD and asthma cases indirectly influence the market potential. The increasing number of pipeline drugs is another factor anticipated to increase the market shortly. However, different Aspergillus species have different levels of intrinsic resistance to azoles. They are all inherently resistant to fluconazole and ketoconazole due to a naturally occurring amino acid substitution in the enzyme 14-sterol demethylase A, which CYP51A encodes can limit the market potential. 

Market Ecosystem

The global invasive aspergillosis therapeutics market has been analyzed from three perspectives: by drug class, route of administration, and region. 

Invasive Aspergillosis Therapeutics Market by Drug Class 

[1245683]

According to drug classes, the market is divided into azoles and antibiotics. Azoles segment has the majority of the market share. Azoles work by inhibiting the growth of the fungus, which helps to reduce the severity of symptoms and prevent further damage. In some cases, azoles may be used in combination with other treatments such as surgery or immunotherapy to provide more effective relief. Azoles have been shown to be effective in treating various forms of invasive aspergillosis, including pulmonary and disseminated forms. Additionally, studies have shown that azoles can help reduce mortality rates associated with this condition. Significant advances in research into the azole class of antifungal agents expanded treatment options for many opportunistic and endemic fungal infections. Among azoles, voriconazole is the primary treatment of invasive aspergillosis. Voriconazole has been shown to be effective in vitro against a variety of yeasts, molds, and aspergillus species. Patients with invasive aspergillosis had a response rate of 48%, according to a non-comparative study covered by the New England journal of medicine. Many azole drugs in the pipeline contribute to segment growth. For instance, TFF VORI inhaled voriconazole by TFF pharmaceuticals is currently in phase two to treat invasive aspergillosis. 

Invasive Aspergillosis Therapeutics Market by Route of Administration

Based on the route of administration, the market is bifurcated into oral and parenteral drugs. The oral route of administration segment has dominated the market. The segment growth is attributed to the availability of major drugs in the oral route of aspergillosis. For instance, voriconazole and posaconazole are two antifungal medications used to treat invasive aspergillosis. Both medications have been shown to be effective in treating this condition, with voriconazole being the preferred drug due to its higher success rate and fewer side effects. However, both drugs can cause serious side effects and should only be used with caution and under the supervision of a doctor. Side effects such as nausea, vomiting, headache, rash, and liver damage can occur with either medication. In patients at high risk for invasive Aspergillus and Candida infections due to severe immunosuppression, Posaconazole (Noxafil) is recommended. It comes in oral solution (200 mg/5 mL), delayed-release tablet (100 mg), and injectable forms. Moreover, for the majority of patients with invasive aspergillosis, oral voriconazole is advised.  L-AmB therapy may be the chief alternative treatment for patients resistant to or intolerant of voriconazole. 

Invasive Aspergillosis Therapeutics Market by Region

Based on region, the global invasive aspergillosis therapeutics market therapy market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America region has dominated the global invasive aspergillosis therapeutics market. Major factors influencing the segment are the increasing number of patients who have experienced organ transplantation. Furthermore, increasing research and development activities in this region is another major factor influencing the market potential in this region. Also, the presence of many market players in the region is another factor increasing the market. For example, SCYNEXIS, Inc., TFF pharmaceuticals, and Mylan Pharmaceuticals, Inc. The Asia Pacific region is anticipated to grow with a high CAGR in the anticipated period. It is a major public health concern in the Asia Pacific region, particularly in countries with high levels of air pollution and poor hygiene. Rising patient population and increasing research activities are major factors influencing the Asia Pacific market. 

Competitive Landscape 

Some of the prominent players operating in the invasive aspergillosis therapeutics market are 

• F2G Ltd.            
• SCYNEXIS, Inc.
• Pulmocide Ltd
• TFF Pharmaceutical, Inc.
• Biosergen AB
• Basilea Pharmaceutical International Ltd. 
• Mylan Pharmaceuticals, Inc.
• Novartis AG
• GlaxoSmithKline plc
• Johnson & Johnson Services Inc. 

Strategic Developments 

• On December 2, 2020, SCYNEXIS and Merck revised their license agreement. As a result, SCYNEXIS no longer owes Merck the two cash milestone payments that it would have made upon the first NDA filing and the first U.S. marketing approval for its NDA for the treatment of VVC, ibrexafungerp, which is projected to happen in June 2021. These monetary milestone payments might have been used for future royalties Merck would have received from the net sales of ibrexafungerp. The modification prevents these milestones from being rewarded in cash, which prevents credits from building up. Additionally, SCYNEXIS will lose the credits it had accrued from a previous milestone payment already made to Merck against future royalties. 

Frequently Asked Questions About This Report